557 related articles for article (PubMed ID: 16398567)
1. Premixed insulin analogues for the treatment of diabetes mellitus.
Garber AJ
Drugs; 2006; 66(1):31-49. PubMed ID: 16398567
[TBL] [Abstract][Full Text] [Related]
2. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.
Ilag LL; Kerr L; Malone JK; Tan MH
Clin Ther; 2007 Jun; 29(6 Pt 1):1254-70. PubMed ID: 18036388
[TBL] [Abstract][Full Text] [Related]
3. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.
Ilag LL; Kerr L; Malone JK; Tan MH
Clin Ther; 2007; 29 Spec No():1254-70. PubMed ID: 18046926
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of biphasic insulin aspart in patients with type 2 diabetes.
Halimi S; Raskin P; Liebl A; Kawamori R; Fulcher G; Yan G
Clin Ther; 2005; 27 Suppl B():S57-74. PubMed ID: 16519038
[TBL] [Abstract][Full Text] [Related]
5. Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus.
Chapman TM; Noble S; Goa KL
Drugs; 2002; 62(13):1945-81. PubMed ID: 12215068
[TBL] [Abstract][Full Text] [Related]
6. Biphasic insulin aspart 30: literature review of adverse events associated with treatment.
Davidson J; Vexiau P; Cucinotta D; Vaz J; Kawamori R
Clin Ther; 2005; 27 Suppl B():S75-88. PubMed ID: 16519039
[TBL] [Abstract][Full Text] [Related]
7. Premixed insulin treatment for type 2 diabetes: analogue or human?
Garber AJ; Ligthelm R; Christiansen JS; Liebl A
Diabetes Obes Metab; 2007 Sep; 9(5):630-9. PubMed ID: 17697056
[TBL] [Abstract][Full Text] [Related]
8. Practical approaches to insulin therapy for type 2 diabetes mellitus with premixed insulin analogues.
Rolla AR; Rakel RE
Clin Ther; 2005 Aug; 27(8):1113-25. PubMed ID: 16199240
[TBL] [Abstract][Full Text] [Related]
9. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients.
Boehm BO; Home PD; Behrend C; Kamp NM; Lindholm A
Diabet Med; 2002 May; 19(5):393-9. PubMed ID: 12027927
[TBL] [Abstract][Full Text] [Related]
10. Defining the role of insulin lispro in the management of postprandial hyperglycaemia in patients with type 2 diabetes mellitus.
Giugliano D; Ceriello A; Razzoli E; Esposito K
Clin Drug Investig; 2008; 28(4):199-210. PubMed ID: 18345710
[TBL] [Abstract][Full Text] [Related]
11. Comparison of thrice daily 'high' vs. 'medium' premixed insulin aspart with respect to evening and overnight glycaemic control in patients with type 2 diabetes.
Ejskjaer N; Rasmussen M; Kamp N; Lindholm A; Christiansen JS
Diabetes Obes Metab; 2003 Nov; 5(6):438-45. PubMed ID: 14617230
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacokinetics and pharmacodynamics of insulin lispro mixtures.
Roach P; Woodworth JR
Clin Pharmacokinet; 2002; 41(13):1043-57. PubMed ID: 12403642
[TBL] [Abstract][Full Text] [Related]
13. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double-blind crossover study in adults with type 2 diabetes mellitus.
McSorley PT; Bell PM; Jacobsen LV; Kristensen A; Lindholm A
Clin Ther; 2002 Apr; 24(4):530-9. PubMed ID: 12017398
[TBL] [Abstract][Full Text] [Related]
14. Biphasic insulin aspart in type 2 diabetes mellitus: an evidence-based medicine review.
Gough SC; Tibaldi J
Clin Drug Investig; 2007; 27(5):299-324. PubMed ID: 17451279
[TBL] [Abstract][Full Text] [Related]
15. Insulin aspart: a review of its use in the management of type 1 or 2 diabetes mellitus.
Reynolds NA; Wagstaff AJ
Drugs; 2004; 64(17):1957-74. PubMed ID: 15329046
[TBL] [Abstract][Full Text] [Related]
16. Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes.
Clements MR; Tits J; Kinsley BT; RĂ¥stam J; Friberg HH; Ligthelm RJ
Diabetes Obes Metab; 2008 Mar; 10(3):229-37. PubMed ID: 18269638
[TBL] [Abstract][Full Text] [Related]
17. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial.
Bretzel RG; Nuber U; Landgraf W; Owens DR; Bradley C; Linn T
Lancet; 2008 Mar; 371(9618):1073-84. PubMed ID: 18374840
[TBL] [Abstract][Full Text] [Related]
18. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomised open-label parallel group four months comparison in patients with type 2 diabetes.
Ligthelm RJ; Mouritzen U; Lynggaard H; Landin-Olsson M; Fox C; le Devehat C; Romero E; Liebl A
Exp Clin Endocrinol Diabetes; 2006 Oct; 114(9):511-9. PubMed ID: 17115349
[TBL] [Abstract][Full Text] [Related]
19. Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily premixed insulin: an open-label, randomised, controlled trial.
Jia W; Xiao X; Ji Q; Ahn KJ; Chuang LM; Bao Y; Pang C; Chen L; Gao F; Tu Y; Li P; Yang J
Lancet Diabetes Endocrinol; 2015 Apr; 3(4):254-62. PubMed ID: 25754414
[TBL] [Abstract][Full Text] [Related]
20. Insulin lispro: a review of its pharmacological properties and therapeutic use in the management of diabetes mellitus.
Wilde MI; McTavish D
Drugs; 1997 Oct; 54(4):597-614. PubMed ID: 9339963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]